Therefore, target-immunity combination drugs (e.g., ICI/VEGFR-TKI) can induce neoantigens and lymphocyte aggregation in the tumor microenvironment, especially in tumors with high expression of neovascularization, intercellular stroma, and proliferative gene signals, effectively mediating immunogenic cell death and exhibiting considerable therapeutic efficacy. The gene discussed is KDR; the disease is neoplasm.